A Study to Evaluate the Evolution of Genotypic Mutations Within the Reverse Transcriptase Region in Partial Virological Responders Who Received Long-Term Entecavir Therapy for Hepatitis B

Trial Profile

A Study to Evaluate the Evolution of Genotypic Mutations Within the Reverse Transcriptase Region in Partial Virological Responders Who Received Long-Term Entecavir Therapy for Hepatitis B

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 28 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top